Cargando…
“Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) – A systematic review and meta-analysis"
BACKGROUND: Recurrent Vulvovaginal Candidiasis (RVVC) is defined as 3 or more episodes of symptomatic Vulvovaginal Candidiasis (VVC) within a year. Out of 75 % of women with VVC, this debilitating infection is experienced by 9 % of women. Although standard guidelines recommend oral and topical fluco...
Autores principales: | Siddiqui, Tasmiyah, Kumar, Kanwal Ashok, Iqbal, Amna, Doultani, Payal Rani, Ashraf, Tayyaba, Eqbal, Farea, Siddiqui, Samrah Inam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618760/ https://www.ncbi.nlm.nih.gov/pubmed/37920530 http://dx.doi.org/10.1016/j.heliyon.2023.e20495 |
Ejemplares similares
-
Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022) -
107. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects with Recurrent Vulvovaginal Candidiasis (ultraViolet)
por: Martens, Mark G, et al.
Publicado: (2021) -
Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis
por: Ge, Gai, et al.
Publicado: (2022) -
Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA
por: Aballéa, Samuel, et al.
Publicado: (2013) -
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
por: Rosati, Diletta, et al.
Publicado: (2020)